Mello Giorgio, Parretti Elena, Marozio Luca, Pizzi Cristina, Lojacono Andrea, Frusca Tiziana, Facchinetti Fabio, Benedetto Chiara
The Maternal-Fetal Medicine High-Risk Pregnancies Unit, University of Florence, Italy.
Hypertension. 2005 Dec;46(6):1270-4. doi: 10.1161/01.HYP.0000188979.74172.4d. Epub 2005 Oct 24.
The role of thrombophilia in the pathogenesis of preeclampsia is controversial. The aim of this case-controlled study was to determine whether thrombophilia increases the risk of preeclampsia or interferes with its clinical course. A total of 808 white patients who developed preeclampsia (cases) and 808 women with previous uneventful pregnancies (controls) matched for age and parity were evaluated for inherited and acquired thrombophilia (factor V Leiden; factor II G20210A; methylenetetrahydrofolate reductase C677T; protein S, protein C, and antithrombin III deficiency; anticardiolipin antibodies; lupus anticoagulant; and hyperhomocysteinemia). Odds ratios (ORs) with 95% confidence intervals (CIs) for risk of being carriers of thrombophilia in cases compared with controls and for risk of maternal life-threatening complications and adverse perinatal outcomes in preeclamptic patients with or without thrombophilia were calculated. Women with severe preeclampsia (406 cases) had a higher risk (OR, 4.9; 95% CI, 3.5 to 6.9) of being carriers of either an inherited or acquired thrombophilic factor, except for protein S, protein C, and antithrombin deficiency. In women with mild preeclampsia (402 cases), only prothrombin and homozygous methylenetetrahydrofolate reductase gene mutations were significantly more prevalent than in the controls. Thrombophilic patients with severe preeclampsia are at increased risk of acute renal failure (OR, 1.8; 95% CI, 1.5 to 2.2), disseminated intravascular coagulation (OR, 2.7; 95% CI, 1.1 to 6.4), abruptio placentae (OR, 2.6; 95% CI, 1.2 to 6.0) and perinatal mortality (OR, 1.7; 95% CI, 1.5 to 2.2) compared with nonthrombophilic preeclamptic patients. Our study demonstrates a significant association between maternal thrombophilia and severe preeclampsia in white women. Thrombophilia also augments the risk of life-threatening maternal complications and adverse perinatal outcomes in preeclamptic patients.
血栓形成倾向在子痫前期发病机制中的作用存在争议。本病例对照研究的目的是确定血栓形成倾向是否会增加子痫前期的风险或干扰其临床病程。对808例发生子痫前期的白人患者(病例组)和808例既往妊娠过程顺利的女性(对照组)进行评估,这些女性在年龄和胎次上相匹配,评估其遗传性和获得性血栓形成倾向(因子V莱顿突变;凝血因子II G20210A突变;亚甲基四氢叶酸还原酶C677T突变;蛋白S、蛋白C和抗凝血酶III缺乏;抗心磷脂抗体;狼疮抗凝物;以及高同型半胱氨酸血症)。计算病例组与对照组相比血栓形成倾向携带者风险的比值比(OR)及95%置信区间(CI),以及有或无血栓形成倾向的子痫前期患者发生危及孕产妇生命的并发症和不良围产期结局的风险。重度子痫前期患者(406例)携带遗传性或获得性血栓形成因子(蛋白S、蛋白C和抗凝血酶缺乏除外)的风险更高(OR为4.9;95%CI为3.5至6.9)。在轻度子痫前期患者(402例)中,只有凝血酶原和亚甲基四氢叶酸还原酶纯合基因突变的发生率显著高于对照组。与非血栓形成倾向的子痫前期患者相比,血栓形成倾向的重度子痫前期患者发生急性肾衰竭(OR为1.8;95%CI为1.5至2.2)、弥散性血管内凝血(OR为2.7;95%CI为1.1至6.4)、胎盘早剥(OR为2.6;95%CI为1.2至6.0)和围产期死亡率(OR为1.7;95%CI为1.5至2.2)的风险增加。我们的研究表明白人女性孕产妇血栓形成倾向与重度子痫前期之间存在显著关联。血栓形成倾向也增加了子痫前期患者发生危及孕产妇生命的并发症和不良围产期结局的风险。